Currently Viewing:
Contributor
CMS Announces Transformative Updates to the MA VBID Model
February 18, 2019
Review Finds VBID Programs Improved Adherence at No Added Cost
August 01, 2018
Value-Based Insurance Design Highlighted at Two Congressional Hearings
July 02, 2018
CMS Rule Creates More Flexibility for Value-Based Benefits in Medicare Advantage
May 25, 2018
High-Deductible Health Plans a Problem for Patients With Cancer
May 10, 2018
Currently Reading
Including VBID Principles Can Avoid Negative Effects of Outcomes-Oriented Contracts
April 19, 2018
Addressing Rising Cost Sharing With Precision Co-Pay Assistance
February 08, 2018
A Year of Value-Based Insurance Design: 2017 Highlights
January 15, 2018
Study Identifies Unexpected Contributor to Rising Health Costs: Low-Cost Services
December 27, 2017
CMS Expands MA VBID Model Test in 2019
December 08, 2017
CMS Proposed Rule Allows Greater Flexibility for VBID in Medicare Advantage
November 25, 2017
Identifying the Top 5 Low-Value Services That Can Be Targeted for Reduction
November 10, 2017
VBID in Action: Connecticut Health Enhancement Plan
March 26, 2017
Healthcare Stakeholders Call for Flexibility in HSA-HDHPs
March 12, 2017
2016 Year in Review: University of Michigan V-BID Center
February 02, 2017
VBID and Medicare Advantage: Achieving Bipartisan Support
November 30, 2016
Understanding Clinical Nuance
October 25, 2016
Implementing VBID in Medicare and Medicare Advantage
October 19, 2016
The Cost of Low-Value Care
October 11, 2016
Adventures in Healthcare: The Dawn of the High-Value Health Plan
October 04, 2016
Reward the Good Soldier: A Dynamic Approach to Consumer Cost-Sharing for Prescription Drugs
September 26, 2016

Including VBID Principles Can Avoid Negative Effects of Outcomes-Oriented Contracts

Since its inception in 2005, the University of Michigan Center for Value-Based Insurance Design (V-BID) has led efforts to promote the development, implementation, and evaluation of innovative health benefit designs balancing cost and quality. A multidisciplinary team of faculty, including A. Mark Fendrick, MD and Michael E. Chernew, PhD, who first published and named the VBID concept, have guided this approach from early principles to widespread adoption in the private and public sectors. The Center has played a key role in the inclusion of VBID in national healthcare reform legislation, as well as in numerous state initiatives. The basic VBID premise is to align patients' out-of-pocket costs, such as copayments, with the value obtained from health services and providers.
This article was collaboratively written by A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design (V-BID), and several V-BID Center staff. 

Outcomes-oriented contracts have the potential to align the interests of patients, health plans, and manufacturers around the goal of responsible healthcare spending while preserving access to care. A new brief from the Center for Value-Based Insurance Design (V-BID), funded by Boehringer Ingelheim, discusses how incorporating principles of VBID can help prevent the negative effects of outcomes-oriented contracting, such as cost-related nonadherence.

Outcomes-oriented contracts are financial arrangements that tie payment to achieving pre-specified clinical goals, and they have received increasing attention for pharmaceutical companies. Research has shown that 70% of payers and 60% of manufacturers polled indicated an interest in outcomes-oriented contracting.1,2 Motivating this interest is a rise in targeted therapies for narrow patient populations. Outcomes-oriented contracts offer a way for payers to offer access to expensive, breakthrough therapies despite the lack of predictability surrounding patient responses.

Outcomes-oriented arrangements can provide a means for payers to prevent excessive expenditures for patients for whom a drug is not appropriate. However, high cost sharing for patients and potential nonadherence should remain the top priority of payment design.

VBID principles can reduce the risk of cost-related nonadherence by aligning patients’ out-of-pocket cost-sharing with the value of the underlying service. This encourages the use of high-value care while also reducing low-value spending. Outcomes-oriented contracts should, therefore, set patient cost sharing at levels that are not burdensome, as well as ensure that utilization management protocols—such as prior authorizations—are not barriers to access.

To read more about the role of VBID and other recommendations for outcomes-oriented contracting, see the full brief.

References
1. Duhig A, Saha S, Smith S, Kaufman S, Hughes J. The current status of outcomes-based contracting for manufacturers and payers: an AMCP membership survey. J Manag Care Spec Pharm. 2017:1-6. doi:10.18553/jmcp.2017.16326.
2. Desai R. Health plans are interested in tying drug payments to patient outcomes. June 16, 2016. http://avalere.com/expertise/life-sciences/insights/health-plans-are-interested-in-tying-drug-payments-to-patient-outcomes. Accessed March 8, 2018.


 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up